

JÃ¼rgen K J Schwarze

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5697817/publications.pdf>

Version: 2024-02-01

105
papers

6,581
citations

50276

46
h-index

66911

78
g-index

110
all docs

110
docs citations

110
times ranked

8631
citing authors

#	ARTICLE	IF	CITATIONS
1	Respiratory Viral Infections in Infants: Causes, Clinical Symptoms, Virology, and Immunology. <i>Clinical Microbiology Reviews</i> , 2010, 23, 74-98.	13.6	590
2	Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. <i>Nature Medicine</i> , 2008, 14, 199-204.	30.7	339
3	The Human Immune Response to Respiratory Syncytial Virus Infection. <i>Clinical Microbiology Reviews</i> , 2017, 30, 481-502.	13.6	264
4	Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab) Tj ETQq0 0 0 rgBT /Overlock 10 recommendations on the use of biologicals in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1023-1042.	5.7	232
5	Alveolar Macrophages Are a Major Determinant of Early Responses to Viral Lung Infection but Do Not Influence Subsequent Disease Development. <i>Journal of Virology</i> , 2008, 82, 4441-4448.	3.4	185
6	The late, but not early, asthmatic response is dependent on IL-5 and correlates with eosinophil infiltration. <i>Journal of Clinical Investigation</i> , 1999, 104, 301-308.	8.2	175
7	Negative regulation of airway responsiveness that is dependent on $\hat{I}^3\hat{I}^1$ T cells and independent of $\hat{I}^2\hat{I}^2$ T cells. <i>Nature Medicine</i> , 1999, 5, 1150-1156.	30.7	166
8	The Human Cathelicidin LL-37 Has Antiviral Activity against Respiratory Syncytial Virus. <i>PLoS ONE</i> , 2013, 8, e73659.	2.5	157
9	EAACI Biologicals Guidelinesâ€”Recommendations for severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 14-44.	5.7	156
10	Development of Eosinophilic Airway Inflammation and Airway Hyperresponsiveness Requires Interleukin-5 but Not Immunoglobulin E or B Lymphocytes. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1999, 21, 480-489.	2.9	152
11	Latency and Persistence of Respiratory Syncytial Virus Despite T Cell Immunity. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 169, 801-805.	5.6	143
12	Anti-interleukin 5 But Not Anti-IgE Prevents Airway Inflammation and Airway Hyperresponsiveness. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1999, 160, 934-941.	5.6	138
13	Plasmacytoid Dendritic Cells Limit Viral Replication, Pulmonary Inflammation, and Airway Hyperresponsiveness in Respiratory Syncytial Virus Infection. <i>Journal of Immunology</i> , 2006, 177, 6263-6270.	0.8	134
14	CD25 ⁺ Natural Regulatory T Cells Are Critical in Limiting Innate and Adaptive Immunity and Resolving Disease following Respiratory Syncytial Virus Infection. <i>Journal of Virology</i> , 2010, 84, 8790-8798.	3.4	133
15	Immunology of COVIDâ€”19: Mechanisms, clinical outcome, diagnostics, and perspectivesâ€”A report of the European Academy of Allergy and Clinical Immunology (EAACI). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2445-2476.	5.7	132
16	HpARI Protein Secreted by a Helminth Parasite Suppresses Interleukin-33. <i>Immunity</i> , 2017, 47, 739-751.e5.	14.8	130
17	Cathelicidins Have Direct Antiviral Activity against Respiratory Syncytial Virus In Vitro and Protective Function In Vivo in Mice and Humans. <i>Journal of Immunology</i> , 2016, 196, 2699-2710.	0.8	129
18	Intranasal corticosteroids in allergic rhinitis in COVIDâ€”19 infected patients: An ARIAâ€”EAACI statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2440-2444.	5.7	114

#	ARTICLE	IF	CITATIONS
19	Sustained increases in numbers of pulmonary dendritic cells after respiratory syncytial virus infection†. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 113, 127-133.	2.9	106
20	The role of pro€resolution lipid mediators in infectious disease. <i>Immunology</i> , 2014, 141, 166-173.	4.4	103
21	Vaccination and allergy: <scp>EAACI</scp> position paper, practical aspects. <i>Pediatric Allergy and Immunology</i> , 2017, 28, 628-640.	2.6	103
22	Bronchiolitis needs a revisit: Distinguishing between virus entities and their treatments. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 40-52.	5.7	103
23	Function of the intestinal epithelium and its dysregulation in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 382-395.	1.9	102
24	Effectiveness of Influenza Vaccines in Asthma: A Systematic Review and Meta-Analysis. <i>Clinical Infectious Diseases</i> , 2017, 65, 1388-1395.	5.8	99
25	Spotlight on microRNAs in allergy and asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1661-1678.	5.7	98
26	A compendium answering 150 questions on COVIDâ€19 and SARSâ€CoVâ€2. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2503-2541.	5.7	95
27	Local treatment with IL-12 is an effective inhibitor of airway hyperresponsiveness and lung eosinophilia after airway challenge in sensitized mice. <i>Journal of Allergy and Clinical Immunology</i> , 1998, 102, 86-93.	2.9	94
28	Enteric helminth-induced type I interferon signaling protects against pulmonary virus infection through interaction with the microbiota. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1068-1078.e6.	2.9	93
29	Handling of allergen immunotherapy in the COVIDâ€19 pandemic: An ARIAâ€EAACI statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1546-1554.	5.7	87
30	Systemic and Local Interferon gamma Gene Delivery to the Lungs for Treatment of Allergen-Induced Airway Hyperresponsiveness in Mice. <i>Human Gene Therapy</i> , 1999, 10, 1905-1914.	2.7	85
31	Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines â€ recommendations on the use of biologicals in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1043-1057.	5.7	85
32	Critical Roles for Interleukin-4 and Interleukin-5 during Respiratory Syncytial Virus Infection in the Development of Airway Hyperresponsiveness after Airway Sensitization. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000, 162, 380-386.	5.6	81
33	COVIDâ€19 pandemic: Practical considerations on the organization of an allergy clinicâ€ An EAACI/ARIA Position Paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 648-676.	5.7	79
34	Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2337-2353.	5.7	78
35	Inhalation of stable dust extract prevents allergen induced airway inflammation and hyperresponsiveness. <i>Thorax</i> , 2006, 61, 134-139.	5.6	69
36	Microbes and asthma: Opportunities for intervention. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 690-697.	2.9	68

#	ARTICLE	IF	CITATIONS
37	ARIAâ€œEAACI statement on severe allergic reactions to COVIDâ€œ19 vaccines â€œ An EAACIâ€œARIA Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1624-1628.	5.7	66
38	Wogonin Induces Eosinophil Apoptosis and Attenuates Allergic Airway Inflammation. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 626-636.	5.6	62
39	Respiratory viral infections as promoters of allergic sensitization and asthma in animal models. European Respiratory Journal, 2002, 19, 341-349.	6.7	60
40	Antigen-specific Immunoglobulin-A Prevents Increased Airway Responsiveness and Lung Eosinophilia after Airway Challenge in Sensitized Mice. American Journal of Respiratory and Critical Care Medicine, 1998, 158, 519-525.	5.6	57
41	ARIAâ€œEAACI statement on asthma and COVIDâ€œ19 (June 2, 2020). Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 689-697.	5.7	57
42	Broad-Spectrum Inhibition of Respiratory Virus Infection by MicroRNA Mimics Targeting p38 MAPK Signaling. Molecular Therapy - Nucleic Acids, 2017, 7, 256-266.	5.1	56
43	The beta2 integrin CD11c distinguishes a subset of cytotoxic pulmonary T cells with potent antiviral effects in vitro and in vivo. Respiratory Research, 2005, 6, 70.	3.6	51
44	Respiratory syncytial virus infection provokes airway remodelling in allergenâ€œexposed mice in absence of prior allergen sensitization. Clinical and Experimental Allergy, 2008, 38, 1016-1024.	2.9	51
45	The Chemokine MIP1Î±/CCL3 Determines Pathology in Primary RSV Infection by Regulating the Balance of T Cell Populations in the Murine Lung. PLoS ONE, 2010, 5, e9381.	2.5	51
46	Local CD11c+MHC Class II~Precursors Generate Lung Dendritic Cells during Respiratory Viral Infection, but Are Depleted in the Process. Journal of Immunology, 2006, 177, 2536-2542.	0.8	49
47	Differential lower airway dendritic cell patterns may reveal distinct endotypes of RSV bronchiolitis. Thorax, 2017, 72, 620-627.	5.6	46
48	Prostaglandin F2Î±-F-Prostanoid Receptor Signaling Promotes Neutrophil Chemotaxis via Chemokine (C-X-C Motif) Ligand 1 in Endometrial Adenocarcinoma. Cancer Research, 2009, 69, 5726-5733.	0.9	45
49	Prostaglandin E ₂ promotes intestinal inflammation via inhibiting microbiota-dependent regulatory T cells. Science Advances, 2021, 7, .	10.3	44
50	Efficacy and safety of dupilumab for moderateâ€œtoâ€œsevere atopic dermatitis: A systematic review for the EAACI biologicals guidelines. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 45-58.	5.7	41
51	Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic. Allergologie Select, 2020, 4, 53-68.	3.1	38
52	Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics. EBioMedicine, 2022, 76, 103856.	6.1	38
53	Healthy but not RSV-infected lung epithelial cells profoundly inhibit T cell activation. Thorax, 2009, 64, 283-290.	5.6	36
54	Impact of preterm birth on brain development and long-term outcome: protocol for a cohort study in Scotland. BMJ Open, 2020, 10, e035854.	1.9	34

#	ARTICLE	IF	CITATIONS
55	Perspective on the host response to human metapneumovirus infection: what can we learn from respiratory syncytial virus infections?. <i>Microbes and Infection</i> , 2006, 8, 285-293.	1.9	31
56	Mer-mediated eosinophil efferocytosis regulates resolution of allergic airway inflammation. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1884-1893.e6.	2.9	28
57	Combination peptide immunotherapy based on <sc>T</sc>-cell epitope mapping reduces allergen-specific <sc>I</sc>g<sc>E</sc> and eosinophilia in allergic airway inflammation. <i>Immunology</i> , 2013, 138, 258-268.	4.4	27
58	Novel insights into immune and inflammatory responses to respiratory viruses. <i>Thorax</i> , 2013, 68, 108-110.	5.6	26
59	COVID-19 pandemic and allergen immunotherapy- an EAACI survey. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3504-3516.	5.7	26
60	Lymphoid and myeloid cell populations in the non-pregnant human Fallopian tube and in ectopic pregnancy. <i>Journal of Reproductive Immunology</i> , 2011, 89, 84-91.	1.9	24
61	ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy. <i>Clinical and Translational Allergy</i> , 2021, 11, e12014.	3.2	24
62	EAACI Biologicals Guidelines- dupilumab for children and adults with moderate-to-severe atopic dermatitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 988-1009.	5.7	24
63	Enhanced virulence, airway inflammation and impaired lung function induced by respiratory syncytial virus deficient in secreted G protein. <i>Thorax</i> , 2004, 59, 517-521.	5.6	23
64	Barometric whole body plethysmography in mice. <i>Journal of Applied Physiology</i> , 2005, 98, 1955-1957.	2.5	21
65	Effector and central memory T helper 2 cells respond differently to peptide immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E784-E793.	7.1	21
66	Hypoxia shapes the immune landscape in lung injury and promotes the persistence of inflammation. <i>Nature Immunology</i> , 2022, 23, 927-939.	14.5	21
67	Nitric oxide induces human CLA + CD25 + Foxp3 + regulatory T cells with skin-homing potential. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1441-1444.e6.	2.9	17
68	Reduced Lung Function in a Chronic Asthma Model Is Associated with Prolonged Inflammation, but Independent of Peribronchial Fibrosis. <i>PLoS ONE</i> , 2008, 3, e1575.	2.5	16
69	Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onset. <i>Expert Review of Molecular Diagnostics</i> , 2011, 11, 197-206.	3.1	16
70	Viral respiratory tract infections and asthma in early life: cause and effect?. <i>Clinical and Experimental Allergy</i> , 2014, 44, 9-19.	2.9	16
71	THE ROLE OF VIRUSES IN DEVELOPMENT OR EXACERBATION OF ATOPIC ASTHMA. <i>Clinics in Chest Medicine</i> , 2000, 21, 279-287.	2.1	15
72	Molecular and cellular mechanisms in the viral exacerbation of asthma. <i>Microbes and Infection</i> , 2008, 10, 1014-1023.	1.9	15

#	ARTICLE	IF	CITATIONS
73	Lung Dendritic Cells in Respiratory Syncytial Virus Bronchiolitis. <i>Pediatric Infectious Disease Journal</i> , 2008, 27, S89-S91.	2.0	15
74	Lung eosinophilsâ€”A novel â€œvirus sinkâ€•that is defective in asthma?. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1832-1834.	5.7	15
75	OX40 Ligand and Programmed Cell Death 1 Ligand 2 Expression on Inflammatory Dendritic Cells Regulates CD4 T Cell Cytokine Production in the Lung during Viral Disease. <i>Journal of Immunology</i> , 2012, 188, 1647-1655.	0.8	14
76	Expression of the B cell differentiation factor BAFF and chemokine CXCL13 in a murine model of Respiratory Syncytial Virus infection. <i>Cytokine</i> , 2018, 110, 267-271.	3.2	14
77	Pulmonary epithelial barrier and immunological functions at birth and in early life - key determinants of the development of asthma?Â A description of the protocol for the Breathing Together study. <i>Wellcome Open Research</i> , 2018, 3, 60.	1.8	14
78	Comparative primary paediatric nasal epithelial cell culture differentiation and RSV-induced cytopathogenesis following culture in two commercial media. <i>PLoS ONE</i> , 2020, 15, e0228229.	2.5	14
79	Evaluating the effectiveness, impact and safety of live attenuated and seasonal inactivated influenza vaccination: protocol for the Seasonal Influenza Vaccination Effectiveness II (SIVE II) study. <i>BMJ Open</i> , 2017, 7, e014200.	1.9	12
80	Respiratory and gastrointestinal epithelial modulation of the immune response during viral infection. <i>Innate Immunity</i> , 2012, 18, 179-189.	2.4	11
81	Viral mimic poly-(I:C) attenuates airway epithelial T-cell suppressive capacity: implications for asthma. <i>European Respiratory Journal</i> , 2016, 48, 1785-1788.	6.7	11
82	Seasonal Influenza Vaccine Effectiveness in People With Asthma: A National Test-Negative Design Case-Control Study. <i>Clinical Infectious Diseases</i> , 2020, 71, e94-e104.	5.8	10
83	Effects of nonâ€steroidal antiâ€inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVIDâ€19. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2337-2354.	5.7	9
84	Preschool wheezing diagnosis and managementâ€“Survey of physiciansâ€™ and caregiversâ€™ perspective. <i>Pediatric Allergy and Immunology</i> , 2020, 31, 206-209.	2.6	8
85	Mcl-1 protects eosinophils from apoptosis and exacerbates allergic airway inflammation. <i>Thorax</i> , 2020, 75, 600-605.	5.6	8
86	Unravelling synergistic immune interactions between respiratory virus infections and allergic airway inflammation. <i>Clinical and Experimental Allergy</i> , 2004, 34, 1153-1155.	2.9	6
87	Effectiveness of mobile health interventions to improve nasal corticosteroid adherence in allergic rhinitis: A systematic review. <i>Clinical and Translational Allergy</i> , 2021, 11, e12075.	3.2	6
88	Peptide immunotherapy for childhood allergy â€•addressing translational challenges. <i>Clinical and Translational Allergy</i> , 2011, 1, 13.	3.2	5
89	Vaccine effectiveness of live attenuated and trivalent inactivated influenza vaccination in 2010/11 to 2015/16: the SIVE II record linkage study. <i>Health Technology Assessment</i> , 2020, 24, 1-66.	2.8	5
90	<i>Pediatric Pulmonology</i></i> year in review 2015: Part 1. <i>Pediatric Pulmonology</i> , 2016, 51, 733-739.	2.0	3

#	ARTICLE	IF	CITATIONS
91	EAACI Research and Outreach Committee: Improving standards and facilitating global collaboration through a Research Excellence Network. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1899-1901.	5.7	3
92	Neosensitization to Allergens after Resolution of Allergic Airways Inflammation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 283-284.	5.6	2
93	Chest auscultatory signs in infants presenting to A&E with bronchiolitis. <i>European Journal of Emergency Medicine</i> , 2014, 21, 436-441.	1.1	2
94	Die Rolle von Virusinfektionen der Atemwege bei Entstehung und Verlauf von asthma bronchiale im Kindesalter. <i>Monatsschrift Fur Kinderheilkunde</i> , 2001, 149, 120-128.	0.1	1
95	Republished: Novel insights into immune and inflammatory responses to respiratory viruses. <i>Postgraduate Medical Journal</i> , 2013, 89, 516-518.	1.8	1
96	Development and implementation of a nurse-led allergy clinic model in primary care: feasibility trial protocol. <i>Npj Primary Care Respiratory Medicine</i> , 2019, 29, 44.	2.6	1
97	Respiratory syncytial virus infection provokes airway remodelling in allergen-exposed mice in absence of prior allergen sensitization. <i>Clinical and Experimental Allergy</i> , 2008, 38, 1241-1241.	2.9	0
98	Mechanisms at the Interface of Innate and Adaptive Immunity in the Pathogenesis of RSV Disease: Lessons from the Mouse Model. <i>Current Respiratory Medicine Reviews</i> , 2011, 7, 176-182.	0.2	0
99	Pediatric pulmonology year in review 2014: Part 2. <i>Pediatric Pulmonology</i> , 2015, 50, 1140-1146.	2.0	0
100	Correspondence to âœBronchiolitis needs a revisit: Distinguishing between virus entities and their treatmentsâœ. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1529-1530.	5.7	0
101	Impact of clinical and patient pathway changes on paediatric research during the national COVID-19 response. <i>Archives of Disease in Childhood</i> , 2021, 106, archdischild-2021-322865.	1.9	0
102	Title is missing!. , 2020, 15, e0228229.		0
103	Title is missing!. , 2020, 15, e0228229.		0
104	Title is missing!. , 2020, 15, e0228229.		0
105	Title is missing!. , 2020, 15, e0228229.		0